Copyright
©The Author(s) 2023.
World J Clin Cases. Feb 26, 2023; 11(6): 1287-1298
Published online Feb 26, 2023. doi: 10.12998/wjcc.v11.i6.1287
Published online Feb 26, 2023. doi: 10.12998/wjcc.v11.i6.1287
Table 1 Demographic information
Patient characteristic | Normoglycemia | Hyperglycemia | Total | P value2 |
Male sex | 102 | 33 | 135 | 0.83 |
54.8% | 53.2% | 54.4% | ||
Vaccinated for COVID | 34 | 10 | 44 | 0.87 |
18.3% | 16.1% | 17.7% | ||
Hypertension | 81 | 36 | 117 | 0.0471 |
43.5% | 58.1% | 47.2% | ||
Family history of diabetes | 16 | 8 | 24 | 0.32 |
8.6% | 12.9% | 9.7% | ||
Prediabetes | 5 | 1 | 6 | 13 |
2.7% | 1.6% | 2.4% | ||
ADA - At risk | 96 | 41 | 137 | 0.05* |
51.6% | 66.1% | 55.2% | ||
Chronic liver disease | 7 | 2 | 9 | 1.00 |
3.8% | 3.2% | 3.6% | ||
Chronic obstructive pulmonary disease | 27 | 7 | 34 | 0.39 |
14.5% | 11.3% | 13.7% | ||
Congestive heart failure | 33 | 7 | 40 | 0.23 |
17.7% | 11.3% | 16.1% | ||
Chronic kidney disease | 31 | 11 | 42 | 0.85 |
16.7% | 17.7% | 16.9% |
Table 2 Demographic information
Variable | Category | n | Mean | Std dev | Median | IQR | P value1 |
Age, yr | Normoglycemic | 186 | 63.38 | 18.52 | 68.50 | 23.00 | 0.366 |
Hyperglycemic | 62 | 66.32 | 15.64 | 65.00 | 29.00 | ||
Weight, kg | Normoglycemic | 186 | 84.96 | 26.24 | 82.50 | 31.00 | 0.982 |
Hyperglycemic | 62 | 84.71 | 25.63 | 82.00 | 29.00 | ||
Height, cm | Normoglycemic | 186 | 168.48 | 10.67 | 166.00 | 18.00 | 0.376 |
Hyperglycemic | 62 | 167.02 | 10.99 | 168.00 | 17.00 | ||
BMI | Normoglycemic | 186 | 29.62 | 7.75 | 28.50 | 9.00 | 0.566 |
Hyperglycemic | 62 | 30.02 | 7.52 | 28.00 | 9.00 |
Table 3 Inflammatory marker levels between the two study groups on admission
Variable | Category | n | Mean | Std dev | Median | IQR | P value2 |
CRP levels on admission | Normoglycemic | 186 | 85.65 | 74.12 | 84.00 | 149.00 | 0.278 |
Hyperglycemic | 62 | 106.56 | 94.09 | 74.00 | 109.00 | ||
Ferritin levels on admission | Normoglycemic | 186 | 470.38 | 984.06 | 385.50 | 1109.50 | 0.0281 |
Hyperglycemic | 62 | 1404.40 | 4758.84 | 124.00 | 647.50 | ||
LDH levels on admission | Normoglycemic | 186 | 224.45 | 245.15 | 276.00 | 319.50 | 0.0411 |
Hyperglycemic | 62 | 319.11 | 326.57 | 231.00 | 389.00 | ||
D-dimer levels on admission | Normoglycemic | 186 | 1.71 | 4.63 | 1.00 | 1.25 | 0.470 |
Hyperglycemic | 62 | 2.15 | 6.26 | 0.00 | 1.00 |
Table 4 Inflammatory marker levels between the two study groups
Table 5 Analyses of outcomes
Table 6 Analyses of outcomes
Table 7 Binary logistic regression for hyperglycemia
Variable | P value | OR | 95%CI for OR | |
Lower | Upper | |||
LDH ≥ 590 U/L | 0.256 | 1.623 | 0.704 | 3.745 |
Hypertension | 0.375 | 1.355 | 0.692 | 2.651 |
Mortality | 0.0241 | 2.528 | 1.129 | 5.662 |
ADA | 0.256 | 0.616 | 0.267 | 1.421 |
Received remdesivir | 0.120 | 1.620 | 0.882 | 2.974 |
- Citation: Geetha HS, Singh G, Sekar A, Gogtay M, Singh Y, Abraham GM, Trivedi N. Hyperglycemia in COVID-19 infection without diabetes mellitus: Association with inflammatory markers. World J Clin Cases 2023; 11(6): 1287-1298
- URL: https://www.wjgnet.com/2307-8960/full/v11/i6/1287.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i6.1287